Kei Amemiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kei Amemiya has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
David M. Waag
Bacteriology Division US Army Medical Research Institute of Infectious Diseases Fort Detrick 21702 Frederick MD USA
3 shared publicationsDavid DeShazer
Bacteriology Division US Army Medical Research Institute of Infectious Diseases Fort Detrick 21702 Frederick MD USA
2 shared publicationsJennifer L. Meyers
Bacteriology Division US Army Medical Research Institute of Infectious Diseases Fort Detrick 21702 Frederick MD USA
2 shared publications- Sarah L. Norris
United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
2 shared publications Gary V. Bush
Pathogenesis and Immunology Branch, Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702
1 shared publicationMarilyn England
Bacteriology Division US Army Medical Research Institute of Infectious Diseases Fort Detrick 21702 Frederick MD USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2007
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 59 (2) , 137-147
Detection of the host immune response to Burkholderia mallei heat-shock proteins GroEL and DnaK in a glanders patient and infected mice
- 1 October 2007
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 59 (2) , 137-147
Open AccessDetection of the host immune response to Burkholderia mallei heat-shock proteins GroEL and DnaK in a glanders patient and infected mice
- Open Access
- 1 May 2002
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (5) , 2319-2325
NonviableBurkholderia malleiInduces a Mixed Th1- and Th2-Like Cytokine Response in BALB/c Mice
Nonviable cell preparations ofBurkholderia mallei, the causative agent of glanders, were evaluated as potential vaccine candidates in a BALB/c murine model. Three differentB. malleicell preparations plus Alhydrogel were evaluated: a heat-killed preparation, an irradiation-inactivated preparation, and a preparation of a capsule-negative mutant strain which had been irradiation inactivated. BALB/c mice were vaccinated twice with the differentB. malleipreparations, and spleens and sera were collected to determine their cellular and humoral immune responses. All three bacterial cell preparations had essentially the same results in two cellular immune response assays. In a splenocyte proliferation assay, the amount of cell proliferation in response to the homologous immunogen, concanavalin A, or lipopolysaccharide was similar for all the cell preparations. Also, splenocytes from the inoculated mice expressed interleukin 2 (IL-2), gamma interferon, and small amounts of IL-4 and IL-5, and more IL-10 cytokine in the presence of the homologous antigen. When the immunoglobulin subclasses from these mice were examined, they all produced higher levels of IgG1 than IgG2a subclasses. The higher ratio of IgG1 to IgG2a was not due to the amount of the immunogen or the adjuvant (Alhydrogel) used in the BALB/c mice. The cell preparations did not protect the vaccinated mice from a live challenge (>300 50% lethal doses). Our results suggest that in BALB/c mice, a mixed T-helper-cell-like response to nonviableB. malleiis obtained, as demonstrated by a Th1- and Th2-like cytokine response and a Th2-like subclass immunoglobulin response. This may be the reason for the inability of theB. malleicells that were examined as candidate vaccines to protect the mice from a live challenge.
- 1 May 2002
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (5) , 2319-2325
Open AccessNonviableBurkholderia malleiInduces a Mixed Th1- and Th2-Like Cytokine Response in BALB/c Mice
Nonviable cell preparations ofBurkholderia mallei, the causative agent of glanders, were evaluated as potential vaccine candidates in a BALB/c murine model. Three differentB. malleicell preparations plus Alhydrogel were evaluated: a heat-killed preparation, an irradiation-inactivated preparation, and a preparation of a capsule-negative mutant strain which had been irradiation inactivated. BALB/c mice were vaccinated twice with the differentB. malleipreparations, and spleens and sera were collected to determine their cellular and humoral immune responses. All three bacterial cell preparations had essentially the same results in two cellular immune response assays. In a splenocyte proliferation assay, the amount of cell proliferation in response to the homologous immunogen, concanavalin A, or lipopolysaccharide was similar for all the cell preparations. Also, splenocytes from the inoculated mice expressed interleukin 2 (IL-2), gamma interferon, and small amounts of IL-4 and IL-5, and more IL-10 cytokine in the presence of the homologous antigen. When the immunoglobulin subclasses from these mice were examined, they all produced higher levels of IgG1 than IgG2a subclasses. The higher ratio of IgG1 to IgG2a was not due to the amount of the immunogen or the adjuvant (Alhydrogel) used in the BALB/c mice. The cell preparations did not protect the vaccinated mice from a live challenge (>300 50% lethal doses). Our results suggest that in BALB/c mice, a mixed T-helper-cell-like response to nonviableB. malleiis obtained, as demonstrated by a Th1- and Th2-like cytokine response and a Th2-like subclass immunoglobulin response. This may be the reason for the inability of theB. malleicells that were examined as candidate vaccines to protect the mice from a live challenge.